“How do I actually get this” is a more complicated question than it should be, because there are three genuinely different pathways with different legal status, oversight, and current availability. Here’s the clear version.
Pathway 1: Prescribed & FDA-Approved
The narrowest but most regulated pathway — a compound with full FDA approval, prescribed by a licensed provider, dispensed by a standard pharmacy. PT-141 (bremelanotide) is the clearest example on this site, approved specifically for HSDD in premenopausal women under the brand name Vyleesi.
Pathway 2: Compounded Through a Licensed Pharmacy
This pathway requires a substance to be on the FDA’s 503A (or in some cases 503B) bulks list, a prescription from a licensed provider, and preparation by a licensed compounding pharmacy. This is where telehealth-prescribed GLP-1 compounds and some other peptides fit — and it’s the pathway the ongoing PCAC review process is specifically about expanding to more substances.
Pathway 3: Research-Use Sourcing
The pathway most of the compounds on this site fall under currently — sold by third-party vendors explicitly for research purposes, not for human consumption, with no prescription or clinical oversight involved. This is where sourcing quality (COAs, vendor transparency) becomes entirely your own responsibility rather than a pharmacy’s.
Which Pathway Should You Actually Use?
If a prescribed option exists for your specific goal — as it does for PT-141 and for GLP-1 compounds through telehealth — that pathway offers the most oversight and is worth strongly considering first. For compounds without an approved or compounding pathway yet, research-use sourcing with careful vendor vetting is the realistic current option. For the prescribed pathway specifically, our sister site Veritide.co covers telehealth provider verification in depth.